Results showed that DMP11 at a dose of 5 nM significantly degraded the BCR-ABL fusion protein of wild-type and imatinib-resistant chronic myeloid leukemia cell lines and found that the SRC protein (Yes/Fyn/Fgr) also showed a dose-dependent degradative effect (Figure 3(a)). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.